Analysts think CLDX stock price could increase by 161%
Oct 27, 2024, 11:26 AM
4.42%
What does CLDX do
Celldex Therapeutics, based in Hampton, New Jersey, develops novel therapeutics targeting mast cell-mediated diseases and employs 160 staff. Their pipeline includes Barzolvolimab and the bispecific antibody CDX-585 for inflammatory diseases and oncology.
12 analysts think CLDX stock price will increase by 161.15%. The current median analyst target is $70.38 compared to a current stock price of $26.95. The lowest analysts target is $44.44 and the highest analyst target is $94.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
